Which has the lower trailing P/E, SYK or VRTX?

SYK has the lower trailing P/E: SYK trades at 28.87 and VRTX at 29.83. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, SYK or VRTX?

Over the past five years, VRTX grew revenue faster — SYK at a 9.72% CAGR versus VRTX at 13.57%.

Does SYK or VRTX pay a bigger dividend?

SYK pays a dividend (1.26% yield), while VRTX has no payments in the available dividend history.

Is SYK or VRTX more profitable?

VRTX runs the higher net margin — SYK at 14.43% versus VRTX at 34.89%.

How have SYK and VRTX total returns compared?

Over the past 10 years, SYK delivered 10.77% and VRTX delivered 18.72% annualized total return. Past performance doesn't predict future results.

Stryker Corporation (SYK) vs Vertex Pharmaceuticals Incorporated (VRTX)

A side-by-side comparison of Stryker Corporation and Vertex Pharmaceuticals Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 13, 2026. Differences are shown without an overall score or investment verdict.

SYK

Stryker Corporation

$106.79B

$278.55HealthcareDelayed quote: Sep 15, 2026, 10:15 AM EDT

VRTX

Vertex Pharmaceuticals Incorporated

$130.06B

$512.43HealthcareDelayed quote: Sep 15, 2026, 10:15 AM EDT

Total return — SYK vs VRTX

growth of $100 · dividends reinvested · last 10y

SYK +200.8% (+11.6%/yr)VRTX +462.1% (+18.8%/yr)VRTX compounded faster over this window

SYK VRTX

SYK vs VRTX: by the numbers

•VRTX is the larger company ($130.06B vs $106.79B market cap).
•SYK trades at the lower trailing earnings multiple (28.87 vs 29.83 P/E), one valuation lens rather than an overall verdict.
•VRTX converts more revenue to profit (34.89% vs 14.43% net margin).
•VRTX grew revenue faster over the past five years (13.57% vs 9.72% CAGR).
•SYK pays a dividend (1.26% yield), while VRTX has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	SYK	VRTX
P/E ratio	28.87	29.83
Forward P/E	18.56	27.33
P/S ratio	4.13	10.30
P/B ratio	4.45	6.42
EV / EBITDA	17.06	24.73
FCF yield	4.40%	2.92%

Profitability

Metric	SYK	VRTX
Gross margin	65.17%	86.04%
Operating margin	22.03%	38.59%
Net margin	14.43%	34.89%
ROE	15.55%	21.76%
ROIC	9.82%	17.33%

Dividends

Metric	SYK	VRTX
Dividend yield	1.26%	N/A
Payout ratio	36.06%	N/A

Growth (annualized)

Metric	SYK	VRTX
Revenue CAGR (5Y)	9.72%	13.57%
EPS CAGR (5Y)	14.79%	8.17%
FCF CAGR (5Y)	9.60%	16.39%
Total return CAGR (5Y)	1.16%	22.61%

Frequently asked

Which has the lower trailing P/E, SYK or VRTX?: SYK has the lower trailing P/E: SYK trades at 28.87 and VRTX at 29.83. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, SYK or VRTX?: Over the past five years, VRTX grew revenue faster — SYK at a 9.72% CAGR versus VRTX at 13.57%.
Does SYK or VRTX pay a bigger dividend?: SYK pays a dividend (1.26% yield), while VRTX has no payments in the available dividend history.
Is SYK or VRTX more profitable?: VRTX runs the higher net margin — SYK at 14.43% versus VRTX at 34.89%.
How have SYK and VRTX total returns compared?: Over the past 10 years, SYK delivered 10.77% and VRTX delivered 18.72% annualized total return. Past performance doesn't predict future results.

Go deeper

Full SYK analysis Full VRTX analysis Interactive comparison tool

Dig into the metrics

Stryker P/E ratio Vertex Pharmaceuticals P/E ratio Stryker dividend yield Stryker ROE Vertex Pharmaceuticals ROE Stryker operating margin Vertex Pharmaceuticals operating margin Stryker revenue growth Vertex Pharmaceuticals revenue growth Stryker free cash flow Vertex Pharmaceuticals free cash flow

Stryker & Vertex Pharmaceuticals appear in these rankings

Highest Operating Margin Stocks Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 13, 2026.